Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Fina ...

LEARSID BIOMEDI Corporate Presentation November 2022 : | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------| | Forward-Looking Statements | | | This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of | 1995, as amended. | Developing and Delivering Treatments that Restore and Preserve Vision for Serious Back of the Eye ...

LEARSID BIOMEDI Corporate Presentation November 2022 : | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------| | Forward-Looking Statements | | | This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of | 1995, as amended. | Developing and Delivering Treatments that Restore and Preserve Vision for Serious Back of the Eye ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Officer, Chief Development Officer Charles Deignan - Chief Financial Officer Dr. Arshad Khanani - Managing Partner at Sierra Eye Associates, Clinical Associate Professor at the University of Nevada Jenny Kobin - Investor Relations Conference Call Participants Andreas Argyrides - Wedbush Annabel Samimy - Stifel John ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | --- | |----------------------------------------------------------------------------|--------------------------------------------------|---- ...

LEARSI BIOMEDI Corporate Presentation August 2022 . Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forwardlooking statements conta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------|---------------------- ...

Clearside Biomedical Inc (NASDAQ:CLSD) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Jenny Kobin - Head of IR George Lasezkay - President, CEO and Director Tom Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - CFO Conference Call Participants Stacy Lee - Stifel Rohit Bhasin - Needham & Company Yi Chen - H.C. Wainwright William Wood - B. Riley Operator Good day, and thank you for standing by. Welcome to the Clearside Biomedical Q2 2022 Financial ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Thomas Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - Chief Financial Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Serge Belanger - Needham Julian Harrison - BTIG Operator Good day ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. | --- | --- | |---------------------------------------------------------------|-----------------------------| | (Exact Name of Reg ...